Neurology focus Leverage Aviva's recent expansion into anti-progranulin recombinant monoclonal antibodies for neurology and inflammatory diagnostics to position advanced biomarker assay development collaborations with neuroscience research groups and diagnostic developers.

Recombinant protein demand capitalize on their Protein on Demand offerings and growing emphasis on recombinant antibodies to target customers seeking semi-custom and custom proteins for preclinical studies and target validation in translational research.

Global reach Explore distributor-led expansions and international research partnerships to widen market access, offering co-developed reagents and assay services for neuroscience, cancer, and immunology across regions with high biotech activity.

Integrated workflows Position Aviva as a one-stop provider that connects discovery, characterization, and measurement for complex biomarkers, selling end-to-end assay development programs that reduce development risk and accelerate assay readiness.

Clinical readiness Target translational and diagnostic-focused teams seeking high-sensitivity, validated antibodies and ECL reagents (AvivaBlot) to de-risk move-from-target-to-assay-ready reagents, emphasizing reliability in real sample matrices.